BioNTech SE

𝐀 𝐭𝐞𝐚𝐦 𝐜𝐨𝐦𝐦𝐢𝐭𝐭𝐞𝐝 𝐭𝐨 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐢𝐧𝐠 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐔.𝐒. "We are at the brink of bringing exciting innovations to patients and we are building something from scratch in the U.S. How many times can you be part of something like this?", says Fatma Ocak, General Manager U.S. Oncology at BioNTech. 🤝 As we expand our U.S. oncology organization and advance pre-launch activities, collaboration and urgency guide our work. Our commitment remains clear: We to provide patients with new treatment options with meaningful impact. If you are driven by science and you work well in a cross-functional environment, you will feel right at home at BioNTech. 🔎 Explore open positions in the U.S.:  https://lnkd.in/d8-eSUCp #TeamBioNTech #WeAreBioNTech #Careers 

At #BioNTech, every day is World Cancer Day. 🎗    The voices from our colleagues shared this week reflect what drives our work every day.    It’s our passion to translate science into survival.    #WorldCancerDay  

Every day, we at #BioNTech are reminded that this mission is deeply personal for many of us.    #WorldCancerDay 

Every day, we at #BioNTech acknowledge that meaningful progress is never achieved by one person alone, but built through collaboration across teams.     #WorldCancerDay 

Every day, we at #BioNTech are inspired by the passion of our colleagues working together towards a bigger goal.   #WorldCancerDay

Every day, we at #BioNTech strive to improve patients’ lives. Our goal is clear: Turn science into survival.    #WorldCancerDay   

𝗞𝘆𝗹𝗶𝗲 𝗝𝗶𝗺𝗲𝗻𝗲𝘇 𝘁𝗼 𝗷𝗼𝗶𝗻 #𝗧𝗲𝗮𝗺𝗕𝗶𝗼𝗡𝗧𝗲𝗰𝗵 🙌 We are excited to welcome Kylie Jimenez as our new Chief People Officer to our Management Board, effective March 1, 2026. In this newly created role, Kylie will lead our global people strategy and drive its execution, strengthen an inclusive culture, and support our journey toward becoming a multi-product oncology company by 2030. At BioNTech, translating science into survival goes hand in hand with fostering an environment where teams can thrive. Dear Kylie Jimenez, welcome to Mainz, welcome to the team, and welcome to the next chapter at #BioNTech. 🚀 🔗 https://lnkd.in/ddaDj2MN

📢 𝟮𝟬𝟮𝟲: 𝗮 𝗱𝗮𝘁𝗮- 𝗮𝗻𝗱 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲-𝗿𝗶𝗰𝗵 𝘆𝗲𝗮𝗿 𝗳𝗼𝗿 𝗕𝗶𝗼𝗡𝗧𝗲𝗰𝗵   At the 44th J.P. Morgan Healthcare Conference, we shared a strategic business update and outlined our 2026 areas of focus as we advance towards our goal of becoming a multi-product oncology company by 2030:    🩺 𝗙𝗿𝗼𝗺 𝗺𝗼𝗱𝗮𝗹𝗶𝘁𝗶𝗲𝘀 𝘁𝗼 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗮𝗿𝗲𝗮𝘀  • Focus on 𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗮𝗿𝗲𝗮𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗺𝗮𝗷𝗼𝗿 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝘆𝗽𝗲𝘀 with the aim of addressing the full continuum of cancer from early- to late-stage disease    🚀 𝗟𝗮𝘁𝗲-𝘀𝘁𝗮𝗴𝗲 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗼𝗻  • Anticipating 𝘀𝗲𝘃𝗲𝗻 𝗹𝗮𝘁𝗲-𝘀𝘁𝗮𝗴𝗲 𝗱𝗮𝘁𝗮 𝗿𝗲𝗮𝗱𝗼𝘂𝘁𝘀 𝗳𝗼𝗿 𝗸𝗲𝘆 𝗮𝘀𝘀𝗲𝘁𝘀 𝗶𝗻 𝟮𝟬𝟮𝟲, and 15 ongoing Phase 3 clinical trials by year-end    🧩 𝗖𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗺𝗼𝗺𝗲𝗻𝘁𝘂𝗺 • 𝟏𝟎+ 𝐨𝐧𝐠𝐨𝐢𝐧𝐠 𝐧𝐨𝐯𝐞𝐥-𝐧𝐨𝐯𝐞𝐥 𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐭𝐫𝐢𝐚𝐥𝐬 exploring combinations of our investigational immunomodulators, ADCs, and mRNA cancer immunotherapies    📊 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻   • Strong financial position supported by COVID-19 vaccine revenue stream, disciplined R&D spend, and strategic partnerships, will continue to enable sustained innovation     Our mission remains clear: to develop transformative therapies with the potential to benefit patients worldwide.    📰 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eUtvsS27    🎥 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘄𝗲𝗯𝗰𝗮𝘀𝘁:    https://lnkd.in/etRWWYJQ    #BioNTech #Oncology #CancerResearch #JPM2026

𝐎𝐮𝐫 𝐒𝐡𝐚𝐫𝐞𝐝 𝐌𝐨𝐦𝐞𝐧𝐭𝐮𝐦 𝐢𝐧 𝟐𝟎𝟐𝟓. How do moments of community become a lived experience? As we reflect on 2025, we recognize the colleagues across #BioNTech who came together through sport – connecting beyond their daily work and strengthening what unites us. 💚 Across sites and regions, these moments reflected commitment, energy and the shared values that shape our culture. From Mainz, Berlin, Idar-Oberstein, Marburg and Munich to Kigali, Melbourne and Singapore, local initiatives brought colleagues together in different ways. Running 🏃, cycling 🚴 and rowing 🚣 became expressions of collaboration and mutual encouragement, creating space for connection. With growing participation across locations, these shared experiences strengthened team spirit and reinforced a sense of belonging. Thank you to everyone who contributed their time, energy and enthusiasm. Your engagement reflects our belief that momentum is created by people – and sustained through the values we live every day. As we look ahead to 2026, we carry this collective energy forward. Strengthened by collaboration, inspired by our colleagues and partners and guided by a shared purpose. #BioNTech #TeamSpirit #BioNTechculture

𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐡𝐚𝐬 𝐜𝐥𝐨𝐬𝐞𝐝 𝐢𝐭𝐬 𝐚𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐂𝐮𝐫𝐞𝐕𝐚𝐜.  🤝 Today, we announced the closing of our acquisition of CureVac, including the completion of the subsequent offering period. With this, CureVac is now part of the BioNTech group. As of today, approx. 86.75% of CureVac’s issued and outstanding shares were validly tendered in the Offer. We expect to complete the acquisition of the remaining shares in January 2026 as part of the previously announced post-offer reorganization. 🧩 With this milestone, we aim to further complement our capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing.  🧭 At BioNTech, we aspire to translate science into survival. With this acquisition, we build on our proven track record and established position in the global mRNA industry and support the execution of our oncology strategy which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and our bispecific antibody candidate targeting PD-L1 and VEGF-A. Read more: https://lnkd.in/e7Vgz88M